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A B S T R A C T
Introduction: Seizures are the most common initial symptom in patients with low-grade glioma and their
occurrence strongly depends on the tumor location. The majority of low-grade gliomas reveal mutations
in the genes encoding isocitrate-dehydrogenase 1 (IDH1) or 2 (IDH2). These mutations are associated
with metabolic changes that are potentially epileptogenic. We investigated the correlation between
IDH1/2 mutations and tumor localization and seizure as the initial symptom.
Materials and methods: This retrospective study included patients with a diagnosis of WHO grade II
astrocytoma and cortical inﬁltration and in whom initial symptoms were documented and biopsy tissue
was available for IDH1/2 analysis. IDH1/2 mutation analysis was performed by direct sequencing or by
immunohistochemistry with an antibody which detects mutated protein IDH1 R132H. Sequencing was
carried out if immunohistochemistry was negative. IDH1/2 status was deﬁned as mutated if either of
these investigations were positive.
Results: Seventy-nine patients were included. IDH1 or IDH2 mutation was present in 63 (80%) patients
who on average were younger than patients without IDH1/2 mutation (40 vs. 47 years, p = 0.0331, t-test).
IDH1/2 mutations were associated with frontal tumor location (p = 0.0202). All 12 tumors in the insula
revealed IDH1/2 mutations. Seizure as the initial symptom was recorded in 57 (72%) patients and was
associated with IDH1 or IDH2 mutation by multivariate analysis (OR 22.563, p = 0.0019).
Conclusion: In WHO grade II astrocytomas, IDH1/2 mutations mostly occur in tumors inﬁltrating the
frontal lobe. Seizure as the initial symptom is associated with IDH1 or IDH2 mutation.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Seizures are the most common initial symptom in patients
suffering from low-grade glioma.1–5 The incidence of seizures
highly depends on the histological ﬁndings as well as tumor
grading. In diffusely inﬁltrating, low-grade gliomas, oligodendrog-
lial histology strongly correlates with seizure.1 Tumor localization* Corresponding author at: Department of Neurosurgery University Medical
Center Go¨ttingen Robert-Koch-Strasse 40 37075 Go¨ttingen, Germany.
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.12.007is another strong predictor for seizures. Patients with temporal,
insular and frontal tumors are likely to have seizures, whereas the
initial symptoms in patients with occipital and deep-seated lesions
are not related to seizures.1,4
However, the etiology of tumor-associated seizures is still not
fully understood.2–4 In about 70–80% of low-grade diffuse gliomas a
mutation of the gene encoding the isocitrate-dehydrogenase
1 (IDH1) and 2 (IDH2) is present.6,7 IDH1 and IDH2 are NADP+-
dependent enzymes located in the cytosol and mitochondria,
respectively. Instead of converting isocitrate to a-ketoglutarate,
mutant IDH1 reduces a-ketoglutarate to 2-hydroxyglutarate (2HG).
Mutant IDH1 supports the reductase rather than the oxidase
activity. This results in a 100-fold raised 2HG level in gliomas with
IDH1 mutation.8Due to the structural similarity to glutamate, 2HG isvier Ltd. All rights reserved.
Table 1
Initial symptoms of 79 patients with grade II astrocytoma according to IDH1/2
mutation status.
Symptoms IDH1/2 mutations IDH1/2 wild-type
Symptomatic focal epilepsy
with secondary generalization
32 4
Symptomatic focal epilepsy 16 3
Others, non-classiﬁable seizures 2 0
Headache 6 5
Focal neurological deﬁcit 5 5
Incidental ﬁndings 2 0
Table 2
Distribution of tumor localization in 79 patients according to IDH1/2 mutation and
seizure as initial symptom.
Site IDH1/2 status Initial symptom
Mutated Wild-type Mutated % Seizure No
seizure
Seizure
in %
Insula 12 0 100 9 3 74
Frontal 40 5 89 33 12 73
Temporal 21 8 72 24 5 83
Parietal 11 5 69 9 7 56
Occipital 3 2 60 1 4 20
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epileptogenic potential of 2HG. In L-2-hydroxyglutarate-acidurea
(2HGA), a rare, probably autosomal recessive disorder, 2HG levels
are elevated in serum, urine and CSF. More than 50% of the mostly
pediatric patients present with severe seizures.10,11
In this retrospective study we investigate whether IDH1 or IDH2
mutations in diffusely inﬁltrating, low-grade gliomas with cortical
inﬁltration correspond with seizures as the initial symptom. We
excluded WHO grade II oligodendrogliomas from our analysis due
to the high frequency of IDH1/2 mutations in these tumors.12 This
distribution would not allow us to set up two groups similar in size
to perform statistical analysis. Therefore, we limited our series to
grade II astrocytomas. Since many glioma patients without
seizures as the initial symptom develop epilepsy during the
clinical course, for manifold reasons,3 we restricted our investiga-
tion to seizure as the initial symptom.
2. Materials and methods
Patients who underwent initial surgery for grade II astrocytoma
at the Neurosurgical Department in Rostock and the Charite´, Berlin,
were selected. The ethic committees of both institutions gave
consent for this analysis. All histological ﬁndings were re-evaluated
according to the established WHO classiﬁcation of brain tumors13by
at least two experienced neuropathologists (AvD, CH). Only patients
who met the following criteria were included in this study: diagnosis
of grade II astrocytoma, available documentation of ﬁrst tumor
symptoms, MRI-proven inﬁltration of cortex, no anticonvulsant
medication prior to the ﬁrst symptom and availability of either fresh
frozen tumor or parafﬁn-embedded tumor tissue.
2.1. Clinical categorization
The clinical ﬁles of the patients were evaluated for initial
symptoms by an independent neurologist specialized in epileptol-
ogy who was not involved in treatment of the patients and was
blinded to the results of IDH1/2 analysis (UL). The ﬁrst symptom
was designated as either ‘‘non-seizure’’ or ‘‘seizure’’ and the
semiology was classiﬁed according to the deﬁnitions by the
International League Against Epilepsy (ILAE) and the International
Bureau for Epilepsy (IBE).14
2.2. Localization
Preoperative MRI scans were reviewed. Inﬁltration of either the
frontal, parietal, occipital, insular or temporal lobe was assigned
when the tumor inﬁltrated more than 1 cm into the cortex of the
according lobe. Tumors extending over multiple lobes gave
multiple counts.
2.3. Determining the mutational status of IDH1/2
The methods and conditions for determining the mutational
status of IDH1 and 2 by direct sequencing of PCR products have
been described previously.6,7Methods and conditions for detecting
the IDH1 R132H mutation by immunohistochemistry (IHC) with
mouse monoclonal antibody H09 (Dianova, catalog number DIA
H09, Hamburg, Germany) on an automated immunostainer
(BenchMark, Ventana Medical Systems, Tuscon, AZ, USA) have
been described in detail elsewhere.15 If no positive staining was
observed the tumors were further processed by direct sequencing.
2.4. Statistical analysis
The statistical analysis for binary data was performed using the
Chi-square test (x2) and multivariate logistic regression (Statistica9, statsoft, Hamburg, Germany). The metric data were analyzed
using the Student’s t-test (GraphPad Prism version 5.00, GraphPad
Software, San Diego California USA, www.graphpad.com). For all
analyses a type I error of a = 5% was deﬁned.
3. Results
79 patients with grade II astrocytoma were included in the
study. The tumors inﬁltrated the frontal lobe in 45 cases, the
temporal lobe in 29, the parietal lobe in 16, the insula in 12 and the
occipital lobe in 5. The median age at ﬁrst operation was 40 years
(range 13–72). Seizure was the initial symptom in 57 (72%)
patients. The other symptoms were focal neurological deﬁcit in 9
and headache in 11 patients. The tumors were incidental ﬁndings
in two patients (Table 1).
Patients with seizure and without seizure as the ﬁrst symptom
had about the same mean age (41.4 vs. 41.7 years, respectively;
p = 0.9179, t-test)
IDH1/2 mutations were detected in 63 (80%) patients. In 61
patients mutations of IDH1 were identiﬁed, resulting in a
replacement of arginine to histidine (R132H) in 59, and arginine
to cysteine (R132C) in 2 patients at position 132. The mutations of
IDH2 resulted in a replacement of arginine to lysine in position 172
(R172K) in 2 patients. All mutations were heterozygous. IDH1 and
IDH2 mutations were exclusive (p < 0.0001, x2-test). Due to the
low number of samples carrying IDH2 mutations we pooled
patients with IDH1 and IDH2 mutations. Patients with IDH1/2
mutations were younger than patients with IDH1/2 wild type
status (mean 40 vs. 47 years, p = 0.0331, t-test).
Seizure as the initial symptom was associated with IDH1/2
mutations (p = 0.001, x2-test).
In regard to tumor location, all 12 tumors (100%) located in the
insula revealed IDH1/2 mutations, in the frontal lobe, 40 out of 45
(89%), in the temporal lobe 21 of 29 (72%), in the parietal lobe 11
of16 (69%) and in the occipital lobe 3 out of 5 (60%) (Table 2).
Tumors inﬁltrating the frontal lobe were associated with an IDH1/2
mutation (p = 0.0202, x2-test).
Seizures were most common in tumors involving the temporal
lobe (27/29; 83%), followed by the insula (9/12; 74%), the frontal
lobe (33/45; 73%) and the parietal lobe (10/17; 59%). Occipital
tumors presented with seizures in only 1 in 5 cases (20%) (Table 2).
Table 3
Seizure-related factors. Multivariate logistic regression reveals IDH1/2 mutation as
the strongest condition for seizure as initial tumor symptoms.
Factor Odds-ratio 95% CI p-Value
IDH1/2 mutation 22.563 3.147–161.745 0.001929
Site
Insula 0.114 0.013–0.965 0.046318
Fronta 0.695 0.164–2.939 0.621102
Parietal 0.511 0.122–2.135 0.357893
Occipital 0.115 0.007–1.743 0.119143
Temporal 8.726 1.3716–55.516 0.021748
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seizure-related initial symptoms (p = 0.0096; x2-test).
Multivariate logistic regression analysis showed that the IDH1/
2 mutation appears to be the strongest predictor for seizure as an
initial symptom, independent of tumor localization (OR 22.563,
p = 0.0019; Table 3).
4. Discussion
We observed an association between seizure as the initial
symptom and mutation of IDH 1 or 2, independent of tumor
localization, in a series of 79 patients suffering from grade II
astrocytoma.
In contrast to our ﬁndings, in a series of 49 glioma patients no
difference in age and seizure as the ﬁrst symptom was reported.16
Since only 7 of these patients had IDH1/2 wild type, these ﬁndings
are prone to type II error. Investigation of initial symptoms was not
in the scope of the study, so there were no inclusion criteria for
cortical inﬁltration or exclusion of deep location. Furthermore, only
37 tumors revealed histology consistent with grade II astrocytoma.
Two tumors had oligodendroglial features and in 10 tumors the
initial diagnosis was based only on MR ﬁndings. Since these features
may have an epileptogenic inﬂuence, we set up strict exclusion
criteria and blinded for classiﬁcation of initial symptoms.
In our study, 72% of patients with astrocytoma grade II
presented with seizures as the initial symptom, which is in line
with the 75% reported by van Breemen et al.2 However, 16% of the
patients in our study revealed unspeciﬁc complaints such as
headache which lead to the tumor diagnosis. A recent study reports
low-grade gliomas as incidental ﬁndings in 9.6%.17 Early MRI
diagnostics in unspeciﬁc complaints was considered to be
responsible for this large number.
Tumor localization is a known strong predictor for tumor-
associated epilepsy. We found the lowest incidence of seizures in
patients with occipital and the highest in patients with temporal,
frontal and insular tumors. This observation is in line with previous
series.1,18 Whereas in our study seizures occurred mostly in
patients with temporal glioma, IDH1/2 mutations appeared most
frequently in tumors of the insula and frontal lobe (Table 1). This
distribution corresponds to the localization pattern of gliomas
with combined deletions of 1p and 19q,19 which are strongly
associated with IDH1/2 mutations.12
Interestingly, all tumors involving the insula revealed IDH1/2
mutations. Given the incidence of IDH1/2 mutation in astrocyto-
mas at 73.6%,7 our series showed statistical signiﬁcance for the
association of IDH1/2 mutation in insular gliomas (p = 0.025).
Many authors have emphasized the unique clinical features of
insula gliomas with frequent seizures and favorable, progression-
free and overall survival.20,21 As IDH1/2 mutations are associated
with prolonged overall survival,16 the high incidence of IDH1/2
mutations in these tumors may explain these ﬁndings.
The pathogenesis of tumor-associated seizures is still not fully
understood.3,4 The strongest evidence for epileptogenesis in low-
grade gliomas comes from microenviromental changes due to tumormetabolism. The report by Olson and co-workers describes a raised
level of the excitatory neurotransmitter glutamate in glioma.22 For
cystine uptake, glutamate is exchanged by the cystine–glutamate–
antiporter xCT. Both glutathione synthesis and xCT expression are
increased in low-grade astrocytomas.23,24 However, high glutamate
levels are associated with malignant gliomas in which seizures are
less frequently observed as initial symptoms.25
In regard to the IDH1/2 mutation-associated changes, further
evidence may be the upstream metabolism. Although IDH1 and
IDH2 presumably are not part of the tricarboxylic acid cycle (TCA),
but IDH3 is, mutation of the former can lead to imbalance, e.g.
scarcity of TCA metabolites, by withdrawal due to 2HG accumula-
tion.8,26 There are numerous reports on seizures in patients or
animal models when the TCA is impaired by inherited disease or
toxic interference.27–29
In clinical practice, seizures frequently improve by radio- or
chemotherapy treatment, even if tumor volume remains un-
changed.30–32 This gives further evidence that tumor metabolism
may cause glioma-induced seizures.
The present data bring up an important issue in terms of tumor
prevalence, survival and progression analysis. Seizure as a ﬁrst
symptom may precede tumor diagnosis33 and thus indicate a
prolonged survival as well as a longer period without tumor
progression.34 In low-grade astrocytomas, presence of the IDH1/2
mutation has actually been shown to be prognostic when the
tumor diagnosis was made on the basis of the ﬁrst symptom,16 and
has shown no prognostic value when only the date of surgery was
considered.35 On the other hand, seizure as the initial symptom is
related to a better overall survival in diffuse gliomas.36,37
5. Limitations
In the present study we observed a correlation between a
particular genetic mutation and clinical symptoms. However, this
is only a correlative study; we do not present additional data that
would allow veriﬁcation of a causal dependency. Furthermore, our
patient cohort is too small for further subgroup analysis, e.g. of
seizure semiology. Retrospective analysis of initial symptoms
based on the patient ﬁles appears to be highly problematic. Only
few patients were treated in departments specialized at diagnosis
of seizures, and we were only able to obtain electroencephalo-
graphic data for single patients. Therefore, there was not sufﬁcient
data on seizure frequency, response to antiepileptic drugs or
changes in semiology, which was mainly due to the decision for
immediate surgery as soon as the tumor was diagnosed.
Nevertheless, tumor surgery would have allowed cortical enceph-
alography on the tumor, which unfortunately was not performed.
This should be carried out in prospective studies.
6. Conclusion
In grade II astrocytomas, IDH1/2 mutations mostly occur in
tumors inﬁltrating the frontal lobe. Seizure as initial symptom is
frequently associated with IDH1/2 mutation. This observation
provides evidence that IDH1/2 mutations and consecutive meta-
bolic changes could result in increased epileptogenic activity.
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